No Detail Found!

Safety and efficacy of alectinib versus crizotinib in alk-positive non- small cell lung cancer: An update meta-analysis

Author(s)
Rui Xiong Department of Pharmacy,General Hospital of Yangtze River Shipping/ Wuhan Bain Hospital,Wuhan,China
Haitan Fu Department of Pharmacy,General Hospital of Yangtze River Shipping/ Wuhan Bain Hospital,Wuhan,China
Qianrui Zhang Department of Pharmacy,General Hospital of Yangtze River Shipping/ Wuhan Bain Hospital,Wuhan,China
Wei Li Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China
Abstract
Our study aimed to evaluate the efficacy and toxicity of alectinib compared with crizotinib and provide a reference for clinical use of ALK-TKI, systematically. We searched articles published update till October, 2021 based on the electronic databases,including PubMed, EMBASE and Cochrane Library. All trials analyzed the summary odds ratios (ORs) of the interesting outcomes. Three RCTs, including six studies were included. The pooled hazard ratio (HR) =0.33 (95%CI=0.21-0.51, P<0.00001) shown that the alectinib group achieved significant progress-free survival (PFS) superiority than crizotinib, consistent with those for the with (P=0.001) or without (P<0.00001) measurable CNS lesions at baseline. Also, the regimen of the alectinib did achieved benefit in the ORR (OR=2.07, 95%CI=1.41-3.06, P=0.0002) than crizotinib. Due to the limited data, the pool result of the difference of overall survival (OS) was without statistically significant (P=0.35). With regard to the safety, grade 3 to 5 adverse events were less frequent with alectinib than crizotinib (OR=0.53, 95%CI=0.31-0.90, P=0.02). As compared with crizotinib, alectinib demonstrated better PFS efficacy and comparable safety as a first-line treatment for advanced ALK-positive Non-Small Cell Lung Cancer (NSCLC). OS data remain immature, further trials with long-term survival rate have future to look forward to.
Publication Details
Page(s) 365-372
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 36, Issue: 2, Year: 2023

Request the full text from PASTIC

Keywords
Meta-analysis, NSCLC, NSCLC, NSCLC, Crizotinib, Alectinib
0

Citations

0

Downloads

61

Views